2KatusHA, PemppisA,LooserS, et al. Enzymelinked immunoassay of cardiac troppnin Tfor the detection of myocardial infarction in patients. J Mol Cell Cardiol,1989,21 (12) :1349 -1953.
1J. C. Marshall. Clinical trials of mediator-directed therapy in sepsis: what have we learned?[J] 2000,Intensive Care Medicine(1):S075～S083
2H. -D. Volk,P. Reinke,D. Krausch,H. Zuckermann,K. Asadullah,J. M. Müller,W. -D. D?cke,W. J. Kox. Monocyte deactivation-rationale for a new therapeutic strategy in sepsis[J] 1996,Intensive Care Medicine(4):S474～S481
6Miksa M, Wu R, Cui X, et al. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator- activated receptor-gamma [J]. J Immunol, 2007, 179(9):6263-6272.
7Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia [J]. Thorax, 2004, 59(5):421-427.
8McNally M, Curtain J, O'Brien KK, et al. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis [J]. British Journal of General Practice, 2010, 60(579):e423-433.
9British Thoracic Society, Myint PK, Kamath AV, et al. Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients [J]. Age Ageing, 2006, 35(3):286-291.
10File TM. The Science of selecting antimicrobials for community acquired pneumonia (CAP) [J]. J Manag Care Pharm, 2009, 15(2):S5-11.
